Prophylix AS is a Norwegian biotech company developing orphan drugs for the prevention of life-threatening or chronically disabling intracranial bleeding in fetuses due to fetal and neonatal alloimmune thrombocytopenia (FNAIT). The lead drug NAITgam contains specific IgG antibodies derived from plasma donated by women with a history of FNAIT in their fetus or newborn.
The NAITgam is developed within the frames of the EU-supported PROFNAIT project, read more at:
www.profnait.eu
Company Details
- Founded
- -
- Address
- Sykehusveien 23, Tromsø,troms 9019,norway
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.prophylix.com
- HQ
- Tromsø, Troms
Prophylix As Questions
Prophylix As's website is http://www.prophylix.com
Prophylix As's LinkedIn profile is https://www.linkedin.com/company/prophylix-as
Prophylix As's industry is
Biotechnology Research
Prophylix As's top competitors are
Prophylix Pharma Holding As,
Axcynsis Therapeutics,
Gambit Bio Llc,
Decktherapeutics, Inc..
Prophylix As's categories are Biotechnology Research
Prophylix As's founding year is 2008
